Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is set to announce third quarter earning results on Friday 6th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AMPH to report 3Q20 income of $ 0.14 per share.
For the full year, analysts anticipate top line of $ 359.59 million, while looking forward to income of $ 0.64 per share bottom line.
Previous Quarter Performance
Amphastar Pharmaceuticals, Inc. unfold income for the second quarter of $ 0.16 per share, from the revenue of $ 85.81 million. According to street consensus, AMPH was expected to report 2Q20 income of $ 0.14 per share from revenue of $ 86.62 million. The bottom line results beat street analysts by $ 0.02 or 14.29 percent, at the same time, top line results fell short of analysts by $ 0.81 million or 0.94 percent.
Stock Performance
Shares of Amphastar Pharmaceuticals, Inc. traded low $ -0.11 or -0.53 percent on Thursday, reaching $ 20.63 with volume of 125.30 thousand shares. Amphastar Pharmaceuticals, Inc. has traded high as $ 21.03 and has cracked $ 20.43 on the downward trend
According to the previous trading day, closing price of $ 20.63, representing a 68.21 % increase from the 52 week low of $ 12.33 and a 8.59 % decrease over the 52 week high of $ 22.69.
The company has a market capital of $ 979.63 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Amphastar Pharmaceuticals, Inc. will be hosting a conference call at 12:00 PM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amphastar.com
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
